ArticlePDF AvailableLiterature Review

A Beneficial Role of Rooibos in Diabetes Mellitus: A Systematic Review and Meta-Analysis

MDPI
Molecules
Authors:

Abstract and Figures

In a rapid increase in cases of diabetes mellitus worldwide, there has been interested in the use of plant-derived polyphenols as nutraceuticals to prevent the onset and progression of diabetes mellitus and its associated complications. Aspalathus linearis, commonly known as rooibos, is a rich source of uncommon glycosylated plant polyphenols with various critical health-promoting properties, including the prevention and treatment of diabetes mellitus (DM). This study aimed to examine these effects by meta-analyzing the current evidence in diabetic rodent models. Peer-reviewed studies written in English from two databases, PubMed and Embase, were searched up to 28 February 2018. Studies reporting blood glucose levels in diabetic rodents with and without receiving rooibos extracts or their major phenolic compounds are included. Twelve studies enrolling 88 diabetic rodents treated with rooibos extracts or their polyphenols and 85 diabetic control males reported blood glucose levels. The pooled effect size was −0.89 (95% CI: −1.44 to −0.35) with a substantial heterogeneity (I² = 67.0%). This effect was likely to be modified by type of rooibos extracts and their polyphenols and treatment period. Blood glucose levels were significantly lower in diabetic rodent models treated with the phenolic compound rich in rooibos extracts, PPAG.
Content may be subject to copyright.
molecules
Article
A Beneficial Role of Rooibos in Diabetes Mellitus:
A Systematic Review and Meta-Analysis
Moe Sasaki 1, Nami Nishida 2and Masako Shimada 1, 2, *ID
1
Graduate School of Nutritional Science, Sagami Women’s University, 2-1-1 Bunkyo, Minami-ku, Sagamihara,
Kanagawa 252-0383, Japan; s1771101@st.sagami-wu.ac.jp
2Faculty of Nutritional Science, Sagami Women’s University, 2-1-1 Bunkyo, Minami-ku, Sagamihara,
Kanagawa 252-0383, Japan; ntake39928@yahoo.co.jp
*Correspondence: shimada_masako@isc.sagami-wu.ac.jp; Tel.: +81-42-742-1927
Academic Editor: Francesca Giampieri
Received: 14 March 2018; Accepted: 5 April 2018; Published: 6 April 2018


Abstract:
In a rapid increase in cases of diabetes mellitus worldwide, there has been interested
in the use of plant-derived polyphenols as nutraceuticals to prevent the onset and progression
of diabetes mellitus and its associated complications. Aspalathus linearis, commonly known
as rooibos, is a rich source of uncommon glycosylated plant polyphenols with various critical
health-promoting properties, including the prevention and treatment of diabetes mellitus (DM).
This study aimed to examine these effects by meta-analyzing the current evidence in diabetic
rodent models. Peer-reviewed studies written in English from two databases, PubMed and Embase,
were searched up to 28 February 2018. Studies reporting blood glucose levels in diabetic rodents
with and without receiving rooibos extracts or their major phenolic compounds are included. Twelve
studies enrolling 88 diabetic rodents treated with rooibos extracts or their polyphenols and 85 diabetic
control males reported blood glucose levels. The pooled effect size was
0.89 (95% CI:
1.44 to
0.35) with a substantial heterogeneity (I
2
= 67.0%). This effect was likely to be modified by type of
rooibos extracts and their polyphenols and treatment period. Blood glucose levels were significantly
lower in diabetic rodent models treated with the phenolic compound rich in rooibos extracts, PPAG.
Keywords: rooibos extracts; diabetic rodent models; blood glucose levels; meta-analysis
1. Introduction
The number of individuals living with diabetes mellitus (DM) was estimated to be 425 million
in 2017 and this figure is expected to reach 629 million by the year 2045 [
1
]. Type 2 DM (T2DM) is a
chronic metabolic disorder that makes up about 90% of DM cases, and primarily occurs as a result of
obesity and lack of exercise. T2DM is characterized by high blood glucose levels, insulin resistance
in the muscle, liver and adipose tissues and relative deficiency of insulin secreted from the pancreas.
Moreover, patients with DM often develop various complications including triopathy, dyslipidemia
and cardiovascular diseases, which are the major causes of their mortality [
1
]. Therefore, it is critical to
explore new strategies to combat DM.
In recent years, there has been a growing interest in various natural products including herbal teas
and traditional Chinese medicinal or desert/semi-desert plants in prevention and treatment of diabetes
due to their natural origin and relatively less side effects than pharmaceuticals [
2
8
]. Aspalathus linearis,
rooibos, is usually grown in the Cederberg, a small mountainous area in the Western Cape province
region of South Africa [
9
]. Compared with green and black teas rooibos tea is a caffeine-free and
low-tannin beverage that contains various minerals and polyphenols, including dihydrochalcones
(aspalathin (ASP) and nothofagin), phenylpropenoids (phenylpyruvic acid-2-O-glucoside (PPAG)),
Molecules 2018,23, 839; doi:10.3390/molecules23040839 www.mdpi.com/journal/molecules
Molecules 2018,23, 839 2 of 15
flavones (isoorientin and orientin) and flavonols (quercetin-3-O-robinobioside). Because of its unique
properties, rooibos tea has gained popularity around the globe, particularly among people such as
expectant and nursing mothers who are encouraged to avoid caffeinated beverages.
Two forms of rooibos teas are available: fermented and unoxidized “green” tea. The fermented
rooibos extracts (FREs) contain high levels of major phenolic compounds, isoorientin (mean
11.8 ±2.6 mg/g
dry powder, 25.2% w/w), orientin (7.9
±
0.7 mg/g, 16.9%), quercetin-3-O-robinobioside
(7.4
±
2.9 mg/g, 15.8%), PPAG (6.7
±
0.4 mg/g, 14.3%) and ASP (3.7
±
0.0 mg/g, 8.1%) [
10
,
11
].
Other flavonoids including nothofagin, vitexin, isovitexin, hyperoside, rutin and isoquercitrin are
also found at a concentration of less than 3 mg/g dry powder of FREs or GREs. Water-based green
rooibos extracts (GREs) contain about three times higher levels of total phenolic compounds than
FREs (GREs, mean 160.6
±
22.7 vs. FREs, 46.7
±
8.0 mg/g dry powder). Quantitative composition
analysis of GREs showed that ASP is the major flavonoid (106.2
±
16.5 mg/g, 66.1% w/w), followed by
isoorientin (13.4
±
2.4 mg/g, 8.3%), nothofagin (11.7
±
2.5 mg/g, 7.3%), orientin (10.6
±
1.6 mg/g,
6.6%), queretin-3-O-robinobiside (6.4
±
0.6 mg/g, 4.0%) and PPAG (2.9
±
0.4 mg/g, 1.8%) [
11
13
].
ASP (C
12
H
24
O
11
, 452.4 Da) and nothofagin (C
21
H
24
O
10
, 436.4 Da) are two major active C-linked
dihydrochalcones uniquely found in rooibos tea. Orientin and isoorientin (C
21
H
20
O
11
, 448.4 Da) are
major C-glycosyl-containing flavones present widely in natural plants, including rooibos. The mean
content of PPAG is similar to or more than ASP in FREs [
10
,
11
]. PPAG concentration in GREs is
approximately 2%; however, that likely varies depending on batches and parts of plants, for example,
stems vs. leaves [1113].
Growing volumes of
in vitro
and
in vivo
data have suggested the potentially beneficial roles
of rooibos tea extracts in glucose metabolism and associated complications, including oxidative
stress, insulin resistance and diabetic myopathy [
14
]. In human subjects, a single dose of rooibos tea
significantly reduced angiotensin-converting enzyme activity [
15
] and increased plasma antioxidant
capacity [
16
], while chronic consumption of fermented rooibos tea improved markers for blood lipid
levels and reduced those of oxidative stress [
17
]. However, no clinical trials have been performed
to examine the effect of rooibos on diabetic parameters. Therefore, the aim of this study was to
assess the effect of rooibos tea and associated polyphenols on blood glucose levels of diabetic rodent
models by meta-analyzing the currently available studies and attempting to sort out the potential
source of heterogeneity that may lead to the discrepancies in the current literature with subgroup and
meta-regression analyses.
2. Results
2.1. Search Results
The flowchart of our literature search is shown in Figure 1. It resulted in a total of 135 articles
(81 from Embase and 54 from PubMed). Upon removal of the duplicates and reviews of the titles and
abstracts, 27 articles moved on to a full-text assessment. Of these, the majority of articles were excluded
from the original meta-analysis because they failed to report blood glucose levels in DM rodent
models treated with rooibos tea extracts or their associated polyphenols. Therefore, 12 studies were
finally included in the meta-analyses [
13
,
18
28
]. There were no articles reporting the effect of either
nothofagin, orientin, or quercetin-3-O-robinobioside alone on blood glucose levels in DM rodents.
Molecules 2018,23, 839 3 of 15
Figure 1. Flow diagram of literature search and selection process.
2.2. Study Characteristics and Quality Assessment
The main characteristics of each included study are summarized in Table 1. Studies were
generally published since 2005. The sample sizes ranged from 10 to 20 in each study. Of the included
studies, animals are treated with FREs in two studies [
18
,
28
], GREs in one study [
13
], ASP in four
studies [19,21,22,26]
, isoorientin in one study [
25
] and PPAG in four studies [
20
,
23
,
24
,
27
]. db/db mice
were used in three studies, ob/ob mice in one study, diet-induced obese insulin-resistant (OBIR)
rodents (in two studies one in rats and one in mice) and KK-Ay mice in one study and streptozotocin
(STZ)-induced DM rodent models in five studies (three in rats and two in mice). Six studies used plasma
for blood glucose measurement, one used serum and five used whole blood samples. Nine studies
assessed glucose levels using fasting blood samples and three using non-fasting samples.
Table 1. Characteristics of included studies in the meta-analysis.
Authors (Year) Rooibos or
Poly-phenols Dose, Route Duration Animal
Models
Total n
(T/no-T)
Age or
Weight at a
Baseline
Diet Fasting or
ad Lib.
Blood
Sample
Ayeleso A et al.,
(2015) [18]FRE
2 g/100 mL
boiling water.
As drinking
water
7 w
STZ-induced
DM rats
(50 mg/kg
i.m.)
16 (8/8) 176–255 g Control Overnight
fasting Plasma
Dludla PV et al.,
(2017) [19]ASP (98%)
13 or
130 mg/kg BW
via daily oral
gavage
6 w db/db mice 12 (6/6) 9 w Control 16-h fasting Plasma
Himpe E et al.,
(2016) [20]PPAG (99%)
10 mg/kg BW
via daily oral
gavage.
11 d
STZ-induced
DM mice (200
mg/kg i.p.)
15 (8/7) 9–11 w,
approx. 25 g Control Ad lib. Whole
blood
Johnson R et al.,
(2017) [21]ASP (98%)
13 or
130 mg/kg/day
via daily oral
gavage
6 w db/db mice 12 (6/6) 9 w Control 4-h fasting Plasma
Kamakura R et al.,
(2015) [13]
GRE (6.62% ASP)
Add to diet at
0.3% and then
0.6%.
5 w KK-Ay mice 11 (5/6) 4 w Control 3-h fasting Whole
blood
Kawano A et al.,
(2009) [22]ASP (98.5%) Added to diet
at 0.2% 5 w db/db mice 10 (4/6) 6 w Control 4-h fasting Whole
blood
Molecules 2018,23, 839 4 of 15
Table 1. Cont.
Authors (Year) Rooibos or
Poly-phenols Dose, Route Duration Animal
Models
Total n
(T/no-T)
Age or
Weight at a
Baseline
Diet Fasting or
ad Lib.
Blood
Sample
Mathijs I et al.,
(2014) [23]PPAG (99%)
10 mg/kg BW
via daily oral
gavage
6 w OBIR mice 13 (7/6) 15 w
High fat
and
fructose
Fasting Whole
blood
Muller CJ et al.,
(2013) [24]PPAG (99%)
0.3–3 mg/kg
BW via daily
oral gavage
3 w OBIR rats 12 (7/5) 24 w
High fat
and
sucrose
4-h fasting Plasma
Sezik E et al., (2005)
[25]isoorientin
15 or 30 mg/kg
BW/d via daily
oral gavage
15 d
STZ-induced
DM rats
(55mg/kg i.p.)
12 (6/6) 200–250 g Control 18–20 h
fasting
Whole
blood
Son MJ et al., (2013)
[26]ASP 0.1% dietary
supplement 5 w ob/ob mice 20 (11/9) 6 w Control 3-h fasting Serum
Song I et al., (2017)
[27]PPAG
A dose of
10 mg/kg BW
via daily oral
gavage
4 d
STZ-induced
DM mice (200
mg/kg i.p.)
20
(10/10)
9–11 w,
approx. 25 g Control Ad lib. Whole
blood
Ulicna O et al.,
(2006) [28]FRE
2.5 g/1L of
boiling water,
5 mL/kg
BW/d via
gavage
9 w
STZ-induced
DM rats
(45 mg/kg i.v.)
20
(10/10) 290–340 g Control Ad lib. Plasma
FRE, fermented rooibos extract; BW, body weight; STZ, streptozotocin; GRE, green rooibos extract; ASP, aspalathin;
PPAG, phenylpyruvic acid-2-O-glucoside; i.v., intravenous, i.m., intramuscular; i.p., intraperitoneal. T, treatment;
no-T, non-treatment.
The detailed quality assessment of each study is shown in Table S1. The study quality was fair in
general with the risk of bias judged to be low to medium.
2.3. Effect of Rooibos Tea Extracts and Associated Polyphenols on Blood Glucose Levels in DM Rodent Models
Twelve studies from 12 articles enrolling 88 diabetic male rodents treated with rooibos extracts or
their major polyphenol compounds, ASP, PPAG and isoorientin and 85 diabetic control males treated
with vehicles reported their blood glucose levels and were included in this meta-analysis (Figure 2).
Four studies showed that treatment with polyphenols, ASP, PPAG and isoorientin, significantly
reduced blood glucose levels in DM rodent models [
24
27
]; eight studies did not observe any significant
effects. By pooling all those studies using a random-effects model, results revealed that rooibos tea
extracts or associated polyphenols reduce blood glucose levels in DM rodents (g =
0.89, 95% CI
1.44 to
0.35; I
2
= 67%, p< 0.001) (Figure 2). To determine the influence of each study on the overall
result, the stability of results was next evaluated using a leave-one-out strategy. Upon removal of
each individual study, all the re-pooled summary estimates remained unchanged compared with the
primary estimates with the effect sizes ranging from
1.00 (95% CI,
1.57 to
0.42) to
0.70 (95% CI,
1.12 to 0.28).
Subgroup analyses suggested that PPAG and isoorientin have significantly reduced blood glucose
levels in DM rodents (PPAG, g =
1.35, 95% CI:
1.89 to
0.81. isoorientin, g =
5.63, 95% CI:
8.11
to
3.15); however, FRE, GRE and ASP have little, if any, effect (Figure 3). Blood glucose levels are not
influenced by type of rodent (mice vs. rats), blood sample (plasma, serum, vs. whole blood), or the
blood sampling time point (non-fasting vs. fasting) (Table 2).
Molecules 2018,23, 839 5 of 15
Figure 2.
Flow diagram of literature search and selection process. Meta-analysis of Hedges’ g of
blood glucose levels in DM rodents with and without treatment of rooibos extracts or associated
major phenolic compounds. Summary estimates were analyzed using a random-effects model. CI,
confidence interval.
Figure 3.
Subgroup analysis for Hedges’ g of blood glucose levels in DM rodents treated with various
types of rooibos extracts and major phenolic compounds or vehicles. Summary estimates were analyzed
using a random-effects model. CI, confidence interval.
Molecules 2018,23, 839 6 of 15
Table 2. Subgroup analyses.
Subgroups Effect Size Heterogeneity (I2)
No. of Studies g95% CI P-value
Rooibos and Polyphenols
FRE 2 0.05 0.58 0.67 0.88 <0.001
GRE 1 1.08 2.25 0.10 0.07 <0.001
ASP 4 0.46 1.03 0.11 0.12 18.12
PPAG 4 1.35 1.89 0.81 <0.001 <0.001
Isoorientin 1 5.63 8.11 3.15 <0.001 <0.001
DM rodent models
db/db 3 0.18 0.80 0.45 0.02 <0.001
ob/ob 1 1.08 1.99 0.17 0.58 <0.001
KK-Ay 1 1.08 2.25 0.10 0.07 <0.001
OBIR 2 1.28 2.10 0.46 0.002 <0.001
STZ 5 1.29 2.54 0.05 0.04 84.65
Rodent
Mice 8 0.84 1.28 0.39 <0.001 30.09
Rats 4 1.41 3.03 0.22 0.09 86.70
Blood sample
Plasma 6 0.54 1.26 0.19 0.15 67.42
Serum 1 1.08 1.99 0.17 0.02 <0.001
Whole blood 5 1.43 2.47 0.39 0.01 70.58
Sampling time point
Non-fasting 3 0.88 2.03 0.27 0.134 77.02
Fasting (>3h) 9 0.91 1.58 0.24 0.007 67.51
2.4. Meta-Regression Analyses
Univariate meta-regression analyses were performed next. Type of rooibos tea extracts and
polyphenols is found to be a significant covariate to explain approximately 100% of between-study
variance (R
2
= 1.0). The treatment period is also, at least in part, responsible for between-study variance
(coefficient = 0.28, 95% CI: 0.11 to 0.45, p< 0.002, R
2
= 0.64) (Figure 4). Moreover, the analyses also
showed that type of rodents, DM models, or blood samples and blood sampling time point do not
affect the variance (R2= 0.00), confirming the results of subgroup analyses described above (Table 2).
Figure 4.
Meta-regression analysis for Hedges’ g of blood glucose levels and treatment period in DM
rodents treated with or without rooibos extracts or major phenolic compounds. Summary estimates
were analyzed using a random-effects model.
Molecules 2018,23, 839 7 of 15
2.5. Publication Bias
No significant evidence of publication bias was observed in the analyses of the effect of rooibos tea
extracts and polyphenols on blood glucose levels as indicated by funnel plots. Moreover, there were
no imputed studies found in re-displayed funnel plots after Duval and Tweedie’s Trim and Fill
adjustment [29,30] (Figure 5).
Figure 5.
Funnel plots of standard error by Hedges’ g of blood glucose levels in DM rodents treated
with or without rooibos extracts or major phenolic compounds. Open and closed diamond indicates
the imputed summary estimates before and after Duval and Tweedie’s Trim and Fill adjustment
(random-effects models), respectively. No imputed studies were found in re-displayed funnel plots by
Duval and Tweedie’s Trim and Fill analysis.
3. Discussion
3.1. Main Findings
To the best of our knowledge, this study is the first meta-analysis that summarizes the evidence
for a possible beneficial role of rooibos extracts and associated polyphenols in blood glucose levels
of DM rodent models. We showed that elevated blood glucose levels of DM rodents are significantly
reduced by intake of FREs, GREs, and their major phenolic compounds compared with those of DM
controls. This association was largely influenced by type of rooibos extracts and their polyphenols
and, at least partly, by treatment period in the subgroup and meta-regression analyses, respectively.
PPAG significantly reduced blood glucose levels in DM mice or rats; however, FREs, GREs, or ASP
failed to demonstrate the similar effects. The chronical treatment with rooibos extracts or their
major polyphenols was thus likely to lose the beneficial effect on reduced glucose levels over time.
Furthermore, types of rodents (mice or rats), DM models (db/db, ob/ob, KK-Ay, OBIR, or STZ-induced)
and blood samples (plasma, serum, or whole blood), or blood sampling time point (fasting or
non-fasting) did not markedly influence the association.
3.2. Interpretation
3.2.1. Structures and Pharmacological Properties of Phenolic Compounds Rich in Rooibos Extracts
The structures of different classes of flavonoids present in the rooibos extracts are shown
in Figure 6.
Molecules 2018,23, 839 8 of 15
Figure 6.
Structures of major flavonoids in rooibos extracts [
14
] Z-2-(
β
-D-glucopyranosyloxy)-3-
phenylpropenoic acid, PPAG.
Two anti-diabetic pharmacological properties are known to be present in rooibos extracts. First,
α
-glucosidase inhibitors are oral anti-diabetic drugs used for treatment of T2DM by preventing glucose
absorption in intestine and thus postprandial hyperglycemia. Muller et al. detected stronger inhibition
of
α
-glucosidase activity in GREs. Further HPLC-based assay confirmed that
α
-glucosidase inhibitory
activity corresponded with the retention time of ASP (Figure 6, top) [
12
]. Moreover, various C-glucoside
flavones detected in rooibos extracts exhibited stronger
α
-glucosidase inhibition activity than acarbose,
one of the most potent
α
-glucosidase inhibitors; the inhibitory activity decreases in the order isoorientin
orientin
isovitrexin
vitrexin. The C-3 hydroxylation of the B-ring of flavones was suggested
to be critical for the inhibition of
α
-glucosidase activity in flavones [
31
] (Figure 6, middle). Flavonols
in rooibos extracts, isoquercitrin and rutin, also showed similar but much weaker
α
-glucosidase
inhibitory activity than acarbose [
32
]. Thus, the glucose lowering effects of rooibos extracts could
be due, at least partly, to the
α
-glucosidase inhibition activity of their contained flavonoids. Second,
inhibition of glucose reabsorption in the kidney became a strategy for lowering blood glucose levels
in T2DM [
33
]. The renal glomerulus filters approximately 160 g of glucose per day, 98% of which is
then reabsorbed primarily in the proximal tubules of nephrons via sodium glucose co-transporters
(SGLTs) [
34
]. Among six known SGLTs in human, SGLT1 and 2 have been well studied. SGLT1 is
located in the small intestine, heart and kidney with an affinity for both glucose and galactose [
35
];
while, SGLT2 is localized only in the kidney with the high selectivity for glucose [
36
,
37
]. Therefore,
chemical compounds with selective inhibition of SGLT2 over SGLT1 and a Glut family, another family
of glucose transporters, would be ideal drug targets against T2DM. Phlorizin, a natural glucosylated
dihydrochalcone present in the bark of apple trees, is the first reported SGLT inhibitor [
38
]. In the
search of new selective drug targets for SGLT2, C-glucoside dihydrochalcones were examined; a line
of research demonstrated the anti-SGLT2 activity in ASP and nothofagin, two major C-glucoside
dihydrochalcone in rooibos [
39
,
40
]. Thus, the anti-SGLT2 property in ASP and nothofagin in rooibos
extracts might also play a critical role in their in vivo anti-diabetic action.
Molecules 2018,23, 839 9 of 15
3.2.2. FREs, GREs and Major Phenolic Compounds in Rooibos in DM Rodent Models
FREs were shown to reduce DM-mediated H
2
O
2
- and ischemia-induced oxidative stress in
STZ-injected DM rats. Aqueous and alkaline extracts of fermented rooibos tea were reported to
significantly lower levels of oxidative stress markers, advanced glycation end products (AGEs) in
plasma and advanced lipoxidation end products, malondialdehyde, in plasma, liver and lends of
STZ-induced DM rats; the extracts also slightly, but not significantly, reduced advanced oxidation
protein products [
28
]. Moreover, FREs increased oxygen radical absorbance capacity, superoxide
dismutase and thiobarbituric acid reactive substances in STZ-induced DM rats [
41
]. However,
FREs alone did not significantly improve plasma glucose and lipid profiles in DM rats [
28
]. Collectively,
FREs might reduce oxidative stress in STZ-induced DM rats. However, consistent with the present
meta-analysis, FREs alone are unlikely to significantly improve plasma glucose and lipid profiles,
at least, in STZ-induced DM rats as reported in control rats [18,42].
In our subgroup analysis which included the solo study using KK-A
y
mice, the chronic treatment
with GREs for more than 3 days showed a trend but failed to exhibit significant beneficial effects on their
blood glucose levels. However, it has been reported that acute and sub-chronical oral administration
of GREs significantly lowered glucose levels in some DM rodent models [
12
]. The underlying
mechanisms by which acute GREs reduce glucose levels could be that GREs stimulate glucose uptake
in muscle [
12
,
13
] and liver cells [
12
], at least in part, by increasing phosphorylation of 5
0
-adenosine
monophosphate-activated protein kinase (AMPK) and serine/threonine kinase (Akt), which then
promotes translocation of glucose transporter 4 (Glut4) to the plasma membrane [
13
]. GREs also
reduced AGE- and H
2
O
2
-induced oxidative stress in pancreatic
β
-cells [
13
]. Moreover, GREs showed
to reverse the palmitate-induced insulin resistance and suppress inflammatory pathway by inhibiting
palmitate-mediated nuclear factor-
κ
B activation in 3T3-L1 adipocytes [
43
]. In summary, GREs have
demonstrated more effective, yet not significant in this study, anti-diabetic potentials than FREs; GREs
might reduce plasma glucose levels in a DM rodent model likely through mechanisms involving
multi-organ systems such as liver, muscle, pancreas and adipose tissue.
The total antioxidant activity of GREs was positively associated with its ASP content [
44
];
therefore, several research examined how ASP alone could modulate glucose metabolism. A study
first compared effects of GREs and ASP alone on glucose metabolism in STZ-induced DM rats [
12
].
The result suggests that GREs are more effective than ASP alone in glucose lowering effect in the
DM mice, which is compatible with our subgroup analysis (ASP;
0.46 (
1.03 to 0.11) p= 0.12
vs. GRE;
1.08 (
2.25 to 0.10) p= 0.07). This was likely because GREs contain other polyphenols
such as rutin [
45
50
] and vitexin/isovitexin [
51
,
52
], which previously showed glucose lowering
effects in STZ-induced DM rats. ASP suppressed the increased fasting blood sugar levels and/or
improved glucose tolerance in two T2DM and obese mouse models, db/db [
22
] and ob/ob [
26
] mice.
The consequent
in vitro
studies demonstrated that these effects were presumably due, at least in part,
to an ASP-mediated dose-dependent increase in glucose uptake in the muscle cells; ASP enhanced
phosphorylation of AMPK and promoted Glut4 translocation to the plasma membrane [
13
,
22
,
26
].
ASP also increased insulin secretion [
22
] and reduced AGE-mediated rise in reactive oxygen species,
a marker for oxidative stress, [
26
] in pancreatic
β
-cells. Collectively, ASP exhibited two anti-diabetic
pharmacological properties, inhibition of both
α
-glucosidase and SGLT2 activities and glucose lowering
effects presumably targeting muscle cells in some T2DM mouse models, however, the present study
failed to display a marked reduction of blood glucose levels by the administration of ASP alone to
DM rodents.
Analysis of infusions prepared from various production batches of fermented rooibos
demonstrated that PPAG is one of the major monomeric phenolic compounds present at similar
concentrations to ASP (Figure 6, bottom) [
53
]. Biological studies showed that PPAG delayed the
onset of diabetes by modifying cell death and necrosis, but not by increasing cell proliferation or its
ability for DNA damage/repair, of pancreatic
β
-cells in STZ-induced DM mice [
20
]. Moreover, PPAG
has been recently shown to improve fasting blood glucose levels, glucose tolerance, insulin levels
Molecules 2018,23, 839 10 of 15
and insulin-resistance in OBIR rats [
24
]. The effects were presumably through increased expression
of glucokinase, Glut 1 and 2, insulin receptor, peroxisome proliferator-activated receptor
α
and
suppressor of cytokine signaling 3 in the liver and through reduced apoptosis or neogenesis of
pancreatic
β
-cells [
24
]. Therefore, these results suggest that PPAG could be a significant modulator
for glucose metabolism in the liver and pancreas in the rodent DM models and our meta-analysis
supports a significant role of PPAG in regulation of blood glucose levels.
The role of isoorientin in STZ-induced DM mice was investigated as the main constituent of
Cecropia obtusifolia or Gentiana olivieri, plants found in Central America (Columbia, Costa Rica, Mexico
and Panama) or Asia, respectively [
25
,
54
]. Aqueous extracts of Cecropia obtusifolia was described for
use of the treatment of diabetes in mice and rabbits [
55
,
56
]. Dried flowering herbs of Gentiana olivieri
in water was used to lower blood glucose levels of T2DM patients [
57
]. The present meta-analysis
based on a single study also suggested the significant glucose lowering effect of isoorientin in DM
rodent models; this could be due to strong pharmacological ability to inhibit
α
-glucosidase activity as
mentioned above. However, the strength of meta-analysis with one study using a dozen rats is quite
low and more future studies will be thus necessary to draw a certain conclusion regarding an effect of
isoorientin on blood glucose levels.
3.2.3. Strength and Limitations
The primary strength of this meta-analysis is the inclusion of relatively large number of DM
mouse and rat models and focusing on an effect of rooibos on their blood glucose levels. We also
systematically assessed various cofounding factors. This meta-analysis has also several limitations.
First, although a broad literature search was applied using two electronic databases, the number
of articles assessing an effect of GREs and isoorientin on blood glucose levels in DM rodents was
quite small and the language restriction and the exclusion of ambiguous literature might increase
the risk of publication bias. Second, some evidence of heterogeneity existed in our meta-analysis
although this could be mostly explained by the pre-specified variables, type of tested rooibos and
related polyphenols as well as treatment period. This heterogeneity may also potentially weaken
the robustness of our findings. Third, all the included studies used male rodents, the outcome could
be different when studies include females. Forth, STZ-induced DM rodent models were generated
after grouping for diet modulation in three included studies [
20
,
27
,
28
]. There exists, at least, a slight
possibility that the investigators’ technical skill for STZ injection could directly or indirectly influenced
the experimental outcome of blood glucose levels.
4. Materials and Methods
4.1. Data Sources and Search Strategies
A comprehensive literature search of the electronic databases PubMed and Embase for
the period between 1 January 1962 and 28 February 2018 was conducted using the keywords
(“Aspalathus linearis or rooibos or aspalathin or nothofagin or PPAG or orientin or isoorientin or
quercetin-3-O-robinobioside) and (diabetes or “insulin resistance”). In addition, the reference lists of
the retrieved articles were manually searched to ensure that no relevant articles had been missed.
4.2. Inclusion and Exclusion Criteria
Peer-reviewed articles in the English language were eligible for inclusion when they fulfilled
the following inclusion criteria: (i) studies used diabetic rodent models with or without treatment
with fermented or green rooibos extracts (FRE and GRE, respectively), PPAG, ASP, nothofagin,
orientin, isoorientin, or quercetin-3-O-robinobioside for more than 3 days; (ii) they also reported
the blood glucose levels of the DM rodents at the end of the treatment period. As the polyphenols
associated with fermented and green rooibos teas, PPAG, ASP, nothofagin, orientin, isoorientin and
quercetin-3-O-robinobioside are included because they were previously reported to be contained
Molecules 2018,23, 839 11 of 15
more than 10% w/w of total phenolic compounds either in FREs or GREs. Studies were excluded if
they are reviews, commentaries, editorials, letters, conference abstracts, duplicates, not in English,
or not studied on blood glucose levels with the treatment for longer than 3 days in rodent DM models.
Unpublished research was not sought. This meta-analysis was strictly conducted according to the
PRISMA guidelines (Table S2).
4.3. Data Extraction and Quality Assessment
Titles and abstracts of retrieved publications were screened initially for potentially eligible
studies, which were subsequently evaluated by full-text review. Data were collected by three authors
(M.S., N.N. and M.S.) in an independent manner using pre-designed standardized data extraction
form; which includes type of rooibos extracts or associated compounds, dose, method and period of
administration, blood glucose levels, baseline age, sex, type of rodent DM models and their relevant
controls. Study quality was assessed by the Cochrane Collaboration “Risk of Bias” Tool [
58
]. The risk of
bias for each quality variable in each criterion was assessed by 2 authors in an independent manner and
judged as “low”, “unclear”, “high”, or “not applicable (N/A)” based on its description in each included
study. Any disagreements in any phase were resolved by discussion until consensus was achieved.
4.4. Data Synthesis and Analysis
Continuous variables were presented as means
±
standard deviation (SD). For studies reporting
the standard errors of means (SEs), the corresponding SDs were calculated by multiplying by the
square root of the respective sample size. For studies providing glucose levels in mmol/L, these levels
were converted into mg/dL using the conversion table offered by the Joslin Diabetic Center at
http://www.joslin.org/info/conversion_table_for_blood_glucose_monitoring.html. For studies
reporting more than one measure of blood glucose levels, the levels after the longest period of
treatment with rooibos extracts or associated compounds and at the treatment dose which gave the
most robust difference in blood glucose levels between the two DM rodent groups were selected and
included in the primary meta-analyses.
Standardized mean difference, Hedges’ g, transformation was used to calculate the related
statistics including variance and 95% CIs of each study and the summary effect size generated in the
meta-analyses and publication bias assessment. The random-effects model was chosen in this study
because it is more conservative and incorporates better between-study variability. Heterogeneity was
assessed using I
2
statistics with its value
50% interpreted as evidence of substantial heterogeneity [
58
].
Subgroup and meta-regression analyses were performed based on type of rooibos extracts and
their major polyphenols (FRE, GRE, ASP, PPAG, or isoorientin), type of blood samples (whole blood,
plasma, or serum), blood sampling time point (fasting vs. ad libitum (ad lib.)), types of rodents
(mice vs. rats) and DM models (db/db, ob/ob, KK-Ay, or STZ-induced) and treatment period to
examine their influence to the outcome estimates. Sensitivity analyses were used to evaluate the
robustness of the outcome estimates mainly by removing one study at a time with a repeat of the
primary meta-analyses. Publication bias was assessed by funnel plots with Duval and Tweedie’s
Trim and Fill analysis (random-effect models). All the statistical analyses were carried out using
Comprehensive Meta-Analysis 3.0 (Biostat, Englewood, NJ, USA) and Review Manager (Version 5.3,
the Nordic Cochrane Center, Copenhagen, Denmark) software.
5. Conclusions
The present meta-analyses demonstrated that blood glucose levels were significantly reduced in
diabetic rodent models treated with PPAG, a rooibos-associated phenolic compound. Some sporadic
case studies reported severe yet reversible adverse effects of rooibos tea on liver in humans [
59
,
60
].
Thus, further clinical studies would be needed to establish the safe and practical use of the rooibos
tea for prevention and treatment of diabetes and its associated complications in humans in the future.
Finally, it would have a profound impact on an increasing number of pre-diabetic patients worldwide,
Molecules 2018,23, 839 12 of 15
in particular, if herbal teas such as rooibos could be developed as natural nutraceuticals for prevention
or delayed onset of diabetes.
Supplementary Materials:
The following are available online. Table S1: Risk of Bias; Table S2: PRISMA checklist.
Acknowledgments:
This research was partially supported by JSPS (Kaken-17K09870) and Sagami Women’s
University (the special research fund (B)) to M.S.
Author Contributions:
M.S., N.N. and M.S. designed the research content, collected, reviewed literature and
analyzed the data; M.S. and M.S. wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
International Diabetes Federation. IDF Diabetes Atlas, 8th ed.; IDF: Brussels, Belgium, 2017; Available online:
http://www.diabetesatlas.org (accessed on 7 March 2018).
2.
Suksomboon, N.; Poolsup, N.; Boonkaew, S.; Suthisisang, C.C. Meta-analysis of the effect of herbal
supplement on glycemic control in type 2 diabetes. J. Ethnopharmacol.
2011
,137, 1328–1333. [CrossRef]
[PubMed]
3.
Li, G.Q.; Kam, A.; Wong, K.H.; Zhou, X.; Omar, E.A.; Alqahtani, A.; Li, K.M.; Razmovski-Naumovski, V.;
Chan, K. Herbal medicines for the management of diabetes. Adv. Exp. Med. Biol.
2012
,771, 396–413.
[PubMed]
4.
Chang, C.L.; Lin, Y.; Bartolome, A.P.; Chen, Y.C.; Chiu, S.C.; Yang, W.C. Herbal therapies for type 2 diabetes
mellitus: Chemistry, biology, and potential application of selected plants and compounds. Evid. Based
Complement. Altern. Med. 2013,2013, 378657. [CrossRef] [PubMed]
5.
Chen, J.; Mangelinckx, S.; Adams, A.; Wang, Z.T.; Li, W.L.; De Kimpe, N. Natural flavonoids as potential
herbal medication for the treatment of diabetes mellitus and its complications. Nat. Prod. Commun.
2015
,10,
187–200. [PubMed]
6.
Kibiti, C.M.; Afolayan, A.J. Herbal therapy: A review of emerging pharmacological tools in the management
of diabetes mellitus in Africa. Pharmacogn. Mag. 2015,11, S258–S274. [CrossRef] [PubMed]
7.
Harlev, E.; Nevo, E.; Mirsky, N.; Ofir, R. Antidiabetic attributes of desert and steppic plants: A review.
Planta Med. 2013,79, 425–436. [CrossRef] [PubMed]
8.
Li, W.L.; Zheng, H.C.; Bukuru, J.; De Kimpe, N. Natural medicines used in the traditional Chinese medical
system for therapy of diabetes mellitus. J. Ethnopharmacol. 2004,92, 1–21. [CrossRef] [PubMed]
9.
McKay, D.L.; Blumberg, J.B. A review of the bioactivity of South African herbal teas: Rooibos (Aspalathus
linearis) and honeybush (Cyclopia intermedia). Phytother. Res. 2007,21, 1–16. [CrossRef] [PubMed]
10.
Dludla, P.V.; Muller, C.J.; Louw, J.; Joubert, E.; Salie, R.; Opoku, A.R.; Johnson, R. The cardioprotective effect
of an aqueous extract of fermented rooibos (Aspalathus linearis) on cultured cardiomyocytes derived from
diabetic rats. Phytomedicine 2014,21, 595–601. [CrossRef] [PubMed]
11.
Mazibuko, S.E.; Muller, C.J.; Joubert, E.; de Beer, D.; Johnson, R.; Opoku, A.R.; Louw, J. Amelioration of
palmitate-induced insulin resistance in C(2)C(1)(2) muscle cells by rooibos (Aspalathus linearis). Phytomedicine
2013,20, 813–819. [CrossRef] [PubMed]
12.
Muller, C.J.; Joubert, E.; de Beer, D.; Sanderson, M.; Malherbe, C.J.; Fey, S.J.; Louw, J. Acute assessment of an
aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential. Phytomedicine
2012,20, 32–39. [CrossRef] [PubMed]
13.
Kamakura, R.; Son, M.J.; de Beer, D.; Joubert, E.; Miura, Y.; Yagasaki, K. Antidiabetic effect of green rooibos
(Aspalathus linearis) extract in cultured cells and type 2 diabetic model KK-A(y) mice. Cytotechnology
2015
,67,
699–710. [CrossRef] [PubMed]
14.
Dludla, P.V.; Joubert, E.; Muller, C.J.F.; Louw, J.; Johnson, R. Hyperglycemia-induced oxidative stress and
heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-beta-D-glucoside.
Nutr. Metab. 2017,14, 45. [CrossRef] [PubMed]
15.
Persson, I.A.; Persson, K.; Hagg, S.; Andersson, R.G. Effects of green tea, black tea and Rooibos tea on
angiotensin-converting enzyme and nitric oxide in healthy volunteers. Public Health Nutr.
2010
,13, 730–737.
[CrossRef] [PubMed]
Molecules 2018,23, 839 13 of 15
16.
Villano, D.; Pecorari, M.; Testa, M.F.; Raguzzini, A.; Stalmach, A.; Crozier, A.; Tubili, C.; Serafini, M.
Unfermented and fermented rooibos teas (Aspalathus linearis) increase plasma total antioxidant capacity in
healthy humans. Food Chem. 2010,123, 679–683. [CrossRef]
17.
Marnewick, J.L.; Rautenbach, F.; Venter, I.; Neethling, H.; Blackhurst, D.M.; Wolmarans, P.; Macharia, M.
Effects of rooibos (Aspalathus linearis) on oxidative stress and biochemical parameters in adults at risk for
cardiovascular disease. J. Ethnopharmacol. 2011,133, 46–52. [CrossRef] [PubMed]
18.
Ayeleso, A.O.; Oguntibeju, O.O.; Brooks, N.L. Impact of Co-administration of Red Palm Oil (Elaeis guineensis
Arecaceae) and Rooibos (Aspalathus linearis Fabaceae) on Glycaemic Parameters, Liver Function and Key
Glycolytic Enzymes in Diabetic Rats. Trop. J. Pharm. Res. 2015,14, 1613–1619. [CrossRef]
19.
Dludla, P.V.; Muller, C.J.; Joubert, E.; Louw, J.; Essop, M.F.; Gabuza, K.B.; Ghoor, S.; Huisamen, B.; Johnson, R.
Aspalathin Protects the Heart against Hyperglycemia-Induced Oxidative Damage by Up-Regulating Nrf2
Expression. Molecules 2017,22, 129. [CrossRef] [PubMed]
20.
Himpe, E.; Cunha, D.A.; Song, I.; Bugliani, M.; Marchetti, P.; Cnop, M.; Bouwens, L. Phenylpropenoic
Acid Glucoside from Rooibos Protects Pancreatic Beta Cells against Cell Death Induced by Acute Injury.
PLoS ONE 2016,11, e0157604. [CrossRef] [PubMed]
21.
Johnson, R.; Dludla, P.V.; Muller, C.J.; Huisamen, B.; Essop, M.F.; Louw, J. The Transcription Profile Unveils
the Cardioprotective Effect of Aspalathin against Lipid Toxicity in an In Vitro H9c2 Model. Molecules
2017
,
22, 219. [CrossRef] [PubMed]
22.
Kawano, A.; Nakamura, H.; Hata, S.; Minakawa, M.; Miura, Y.; Yagasaki, K. Hypoglycemic effect of
aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice.
Phytomedicine 2009,16, 437–443. [CrossRef] [PubMed]
23.
Mathijs, I.; Da Cunha, D.A.; Himpe, E.; Ladriere, L.; Chellan, N.; Roux, C.R.; Joubert, E.; Muller, C.; Cnop, M.;
Louw, J.; et al. Phenylpropenoic acid glucoside augments pancreatic beta cell mass in high-fat diet-fed mice
and protects beta cells from ER stress-induced apoptosis. Mol. Nutr. Food Res.
2014
,58, 1980–1990. [CrossRef]
[PubMed]
24.
Muller, C.J.; Joubert, E.; Pheiffer, C.; Ghoor, S.; Sanderson, M.; Chellan, N.; Fey, S.J.; Louw, J.
Z-2-(beta-D-glucopyranosyloxy)-3-phenylpropenoic acid, an alpha-hydroxy acid from rooibos (Aspalathus
linearis) with hypoglycemic activity. Mol. Nutr. Food Res. 2013,57, 2216–2222. [CrossRef] [PubMed]
25.
Sezik, E.; Aslan, M.; Yesilada, E.; Ito, S. Hypoglycaemic activity of Gentiana olivieri and isolation of the active
constituent through bioassay-directed fractionation techniques. Life Sci.
2005
,76, 1223–1238. [CrossRef]
[PubMed]
26.
Son, M.J.; Minakawa, M.; Miura, Y.; Yagasaki, K. Aspalathin improves hyperglycemia and glucose intolerance
in obese diabetic ob/ob mice. Eur. J. Nutr. 2013,52, 1607–1619. [CrossRef] [PubMed]
27.
Song, I.; Roels, S.; Martens, G.A.; Bouwens, L. Circulating microRNA-375 as biomarker of pancreatic beta
cell death and protection of beta cell mass by cytoprotective compounds. PLoS ONE
2017
,12, e0186480.
[CrossRef] [PubMed]
28.
Ulicna, O.; Vancova, O.; Bozek, P.; Carsky, J.; Sebekova, K.; Boor, P.; Nakano, M.; Greksak, M. Rooibos tea
(Aspalathus linearis) partially prevents oxidative stress in streptozotocin-induced diabetic rats. Physiol. Res.
2006,55, 157–164. [PubMed]
29.
Duval, S.; Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for
publication bias in meta-analysis. Biometrics 2000,56, 455–463. [CrossRef] [PubMed]
30.
Duval, S.; Tweedie, R. A nonparametric ‘trim and fill’ method of accounting for publication bias in
meta-analysis. J. Am. Stat. Assoc. 2000,95, 89–98.
31.
Li, H.; Song, F.; Xing, J.; Tsao, R.; Liu, Z.; Liu, S. Screening and structural characterization of alpha-glucosidase
inhibitors from hawthorn leaf flavonoids extract by ultrafiltration LC-DAD-MS(n) and SORI-CID FTICR MS.
J. Am. Soc. Mass Spectrom. 2009,20, 1496–1503. [CrossRef] [PubMed]
32.
Li, Y.Q.; Zhou, F.C.; Gao, F.; Bian, J.S.; Shan, F. Comparative evaluation of quercetin, isoquercetin and rutin
as inhibitors of alpha-glucosidase. J. Agric. Food Chem. 2009,57, 11463–11468. [CrossRef] [PubMed]
33.
Kinne, R.K.; Castaneda, F. SGLT inhibitors as new therapeutic tools in the treatment of diabetes.
In Diabetes-Perspectives in Drug Therapy; Springer: Berlin/Heidelberg, Germany, 2011; pp. 105–126. [CrossRef]
34.
Vallon, V.; Thomson, S.C. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic
effects of SGLT2 inhibition. Diabetologia 2017,60, 215–225. [CrossRef] [PubMed]
Molecules 2018,23, 839 14 of 15
35.
Evans, L.; Grasset, E.; Heyman, M.; Dumontier, A.M.; Beau, J.P.; Desjeux, J.F. Congenital selective
malabsorption of glucose and galactose. J. Pediatr. Gastroenterol. Nutr.
1985
,4, 878–886. [CrossRef]
[PubMed]
36.
Kanai, Y.; Lee, W.S.; You, G.; Brown, D.; Hediger, M.A. The human kidney low affinity Na+/glucose
cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J. Clin. Investig.
1994,93, 397–404. [CrossRef] [PubMed]
37.
Idris, I.; Donnelly, R. Sodium-glucose co-transporter-2 inhibitors: An emerging new class of oral antidiabetic
drug. Diabetes Obes. Metab. 2009,11, 79–88. [CrossRef] [PubMed]
38.
Rossetti, L.; Smith, D.; Shulman, G.I.; Papachristou, D.; DeFronzo, R.A. Correction of hyperglycemia with
phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Investig.
1987
,79, 1510–1515.
[CrossRef] [PubMed]
39.
Jesus, A.R.; Vila-Vicosa, D.; Machuqueiro, M.; Marques, A.P.; Dore, T.M.; Rauter, A.P. Targeting Type
2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2)
Inhibitors: Synthesis and Biological Evaluation. J. Med. Chem. 2017,60, 568–579. [CrossRef] [PubMed]
40.
Lui, W.; Wang, H.; Meng, F. In silico modeling of aspalathin and nothofagin against SGLT2. J. Ther.
Comput. Chem. 2015,14, 15550056.
41.
Ayeleso, A.; Brooks, N.; Oguntibeju, O. Modulation of antioxidant status in streptozotocin-induced diabetic
male Wistar rats following intake of red palm oil and/or rooibos. Asian Pac. J. Trop. Med.
2014
,7, 536–544.
[CrossRef]
42.
Ayeleso, A.; Oguntibeju, O.O.; Brooks, N.L. Assessment of Lipid Profiles, Antioxidant Status and Liver
Histopathology in Male Wistar Rats Following Dietary Intake of Rooibos (Aspalathus linearis). Int. J. Pharmacol.
2013,9, 348–357. [CrossRef]
43.
Mazibuko, S.E.; Joubert, E.; Johnson, R.; Louw, J.; Opoku, A.R.; Muller, C.J. Aspalathin improves glucose
and lipid metabolism in 3T3-L1 adipocytes exposed to palmitate. Mol. Nutr. Food Res.
2015
,59, 2199–2208.
[CrossRef] [PubMed]
44.
Joubert, E.; Gelderblom, W.C.; Louw, A.; de Beer, D. South African herbal teas: Aspalathus linearis, Cyclopia
spp. and Athrixia phylicoides—A review. J. Ethnopharmacol. 2008,119, 376–412. [CrossRef] [PubMed]
45.
Fernandes, A.A.; Novelli, E.L.; Okoshi, K.; Okoshi, M.P.; Di Muzio, B.P.; Guimaraes, J.F.; Fernandes Junior, A.
Influence of rutin treatment on biochemical alterations in experimental diabetes. Biomed. Pharmacother.
2010
,
64, 214–219. [CrossRef] [PubMed]
46.
Kamalakkannan, N.; Prince, P.S. Antihyperglycaemic and antioxidant effect of rutin, a polyphenolic
flavonoid, in streptozotocin-induced diabetic wistar rats. Basic Clin. Pharmacol. Toxicol.
2006
,98, 97–103.
[CrossRef] [PubMed]
47.
Panchal, S.K.; Poudyal, H.; Arumugam, T.V.; Brown, L. Rutin attenuates metabolic changes, nonalcoholic
steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J. Nutr.
2011
,
141, 1062–1069. [CrossRef] [PubMed]
48.
Stanely Mainzen Prince, P.; Kannan, N.K. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing
enzymes and glycoproteins in streptozotocin-induced diabetic rats. J. Pharm. Pharmacol.
2006
,58, 1373–1383.
[CrossRef] [PubMed]
49.
Lee, D.G.; Jang, I.S.; Yang, K.E.; Yoon, S.J.; Baek, S.; Lee, J.Y.; Suzuki, T.; Chung, K.Y.; Woo, S.H.; Choi, J.S.
Effect of rutin from tartary buckwheat sprout on serum glucose-lowering in animal model of type 2 diabetes.
Acta Pharm. 2016,66, 297–302. [CrossRef] [PubMed]
50.
Yuan, X.; Wei, G.; You, Y.; Huang, Y.; Lee, H.J.; Dong, M.; Lin, J.; Hu, T.; Zhang, H.; Zhang, C.; et al. Rutin
ameliorates obesity through brown fat activation. FASEB J. 2017,31, 333–345. [CrossRef] [PubMed]
51.
Choo, C.Y.; Sulong, N.Y.; Man, F.; Wong, T.W. Vitexin and isovitexin from the Leaves of Ficus deltoidea with
in-vivo alpha-glucosidase inhibition. J. Ethnopharmacol. 2012,142, 776–781. [CrossRef] [PubMed]
52.
Nurdiana, S.; Goh, Y.M.; Ahmad, H.; Dom, S.M.; Syimal’ain Azmi, N.; Noor Mohamad Zin, N.S.; Ebrahimi, M.
Changes in pancreatic histology, insulin secretion and oxidative status in diabetic rats following treatment
with Ficus deltoidea and vitexin. BMC Complement. Altern. Med. 2017,17, 290. [CrossRef] [PubMed]
53.
Joubert, E.; de Beer, D.; Malherbe, C.J.; Muller, N.; Bonnet, S.L.; van der Westhuizen, J.H.; Ferreira, D.
Occurrence and sensory perception of Z-2-(
β
-D-glucopyranosyloxy)-3-phenylpropenoic acid in rooibos
(Aspalathus linearis). Food Chem. 2013,136, 1078–1085. [CrossRef] [PubMed]
Molecules 2018,23, 839 15 of 15
54.
Andrade-Cetto, A.; Wiedenfeld, H. Hypoglycemic effect of Cecropia obtusifolia on streptozotocin diabetic
rats. J. Ethnopharmacol. 2001,78, 145–149. [CrossRef]
55.
Perez, R.M.; Ocegueda, A.; Munoz, J.L.; Avila, J.G.; Morrow, W.W. A study of the hypoglycemic effect of
some Mexican plants. J. Ethnopharmacol. 1984,12, 253–262. [CrossRef]
56.
Roman-Ramos, R.; Flores-Saenz, J.L.; Partida-Hernandez, G.; Lara-Lemus, A.; Alarcon-Aguilar, F.
Experimental study of the hypoglycemic effect of some antidiabetic plants. Arch. Investig. Med.
1991
,
22, 87–93.
57. Baser, K.H.C.; Honda, G.; Miki, W. Herb Drugs and Herbalists in Turkey; ILCAA: Tokyo, Japan, 1986; p. 27.
58.
The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0; The
Cochrane Collaboration: London, UK, 2017; Available online: https://training.cochrane.org/handbook
(accessed on 7 March 2018).
59.
Engels, M.; Wang, C.; Matoso, A.; Maidan, E.; Wands, J. Tea not Tincture: Hepatotoxicity Associated with
Rooibos Herbal Tea. ACG Case Rep. J. 2013,1, 58–60. [CrossRef] [PubMed]
60.
Sinisalo, M.; Enkovaara, A.L.; Kivisto, K.T. Possible hepatotoxic effect of rooibos tea: a case report. Eur. J.
Clin. Pharmacol. 2010,66, 427–428. [CrossRef] [PubMed]
©
2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Supplementary resource (1)

Data
April 2018
Moe Sasaki · Nami Nishida · Masako Shimada
... Traditional medicinal uses of Rooibos in South Africa include alleviating infantile colic, allergies, asthma, and dermatological problems [22]. It is asserted that Rooibos has a low toxicity profile with several health benefits [19,23] which include antioxidant [24], antiaging [25], anticancer [26], anti-inflammatory [27], antimutagenic [28] and antidiabetic [29] properties. ...
... The flavonol, kaempferol (28)also found in Honeybush -showed the best affinity for the A 1 AR in the series (rA 1 K i = 0.729 μM; hA 1 K i = 9.88 μM). Compounds structurally related to kaempferol, such as kaempferide (29) and rhamnocitrin (30)although not present ...
Article
Full-text available
Rooibos (Aspalathus linearis) and Honeybush (Cyclopia intermedia) are popular tisanes in South Africa and are of growing interest due to the wide variety of flavonoids and other phytochemicals they contain. Despite their history as herbal teas and traditional medicines, the chemical constituents of these tisanes have yet to be studied for their effects on adenosine receptors. A series of 30 commercially available chemical constituents of Rooibos and Honeybush were investigated via radioligand binding studies to determine their adenosine A1 and A2A receptor affinity at both rat and human subtypes in order to establish structure-activity relationships and identify novel adenosine receptor ligands. In addition, in silico evaluations of the 30 test compounds were also performed to predict their physiochemical and pharmacokinetic properties. The most promising chemical constituent was kaempferol (28) which showed sub-micromolar affinity towards the rat A1 subtype (rA1Ki = 0.7287 μM; hA1Ki = 9.88 µM) and acted as an antagonist toward adenosine rA1 receptors. Additionally, quercetin (2), chrysoeriol (8), luteolin (9), eriodyctiol (12), and naringenin (27) also showed adenosine A1 and/or A2A receptor affinity. It was observed that a flavonol scaffold is preferred to flavone and flavanone scaffolds, and within the flavonols, C4’-OH substitution on ring B is preferred to C3’,4’-diOH substitution. These phytochemicals, specifically kaempferol (28), may be considered lead-like and valuable in designing novel ligands, based on in vitro and in silico evaluation.
... Rooibos (Aspalathus linearis), a shrub from the Fabaceae family is a commercially available traditional herbal tea, grown in the Cederberg in the Western Cape province region of South Africa and has been reported to have many healthpromoting properties [1,2]. It is available commercially as a fermented and non-fermented beverage [3] and studies have reported that extracts from rooibos tea are caffeine-free and have antioxidant properties due to the presence of polyphenolic compounds such as dihydrochalcone C-glucosides aspalathin and nothofagin, and other polyphenols such as vitexin, isovitexin, luteolin, chrysoeriol, quercetin, isoquercetin and rutin and thus are potential anti-ageing agents which can combat oxidative stress [4][5]. ...
Article
Full-text available
Studies have reported that extracts from rooibos and green tea are rich in antioxidants and this study investigated their antioxidant activity using an oxygen radical absorbance capacity (ORAC) assay. Permeability assays were also performed to determine the extent of polyphenol absorption across the membrane using permeability models such as parallel artificial membrane permeability assay (PAMPA), cellular antioxidant and CAPe assays. The ORAC assay confirmed the antioxidant capacity of rooibos extracts, and their permeability was assessed using the PAMPA assay, with rooibos extracts presenting a permeation coefficient comparable to that of rifampicin, which is 11 x 10-6 cm.s-1. In a cellular context, the ability of rooibos extracts to permeate U937 and red blood cell membranes and inhibit the oxidation of 2,7-dichloro-dihydro-fluorescein diacetate (DCFH-DA) to DCF within the cells was confirmed with green rooibos exhibiting a higher activity with an IC 50 value of 22 and 71 μg.ml-1 , in U937 and red blood cells, respectively and fermented rooibos with IC 50 values of 49 and 221 μg.ml-1 for U937 and red blood cells, respectively. This confirmed the ability of rooibos extracts to permeate cell membranes and inhibit oxidative stress by inhibiting the oxidation of DCFH-DA within the cells.
... There are different types of tea, namely black, yellow, green, oolong, white, and Pu-erh. Each has its own unique (aspalathin and nothofagin), flavones (isoorientin, orientin, and vitexin), flavonols (quercetin and rutin), phenylpropenoids (phenylpyruvic acid-2-O-glucoside) as well as phenolic acids, catechins and coumarins [9,11,14,15]. The untargeted metabolomic-based analysis of rooibos herbal tea conducted by Damiani et al. indicated the presence of 187 phenolic compounds, mostly flavonoids, tyrosols, and phenolic acids [16]. ...
Article
Full-text available
Rooibos herbal tea prepared from Aspalathus linearis is becoming increasingly popular. The main aim of this study was to compare the differences in the content of antioxidant compounds between green and fermented rooibos, and white, green, Pu-erh, and black Camellia sinensis teas. Overall, higher antioxidant capacity was measured for infusions prepared from unfermented leaves than fermented of both plants. The use of high-performance liquid chromatography-tandem mass spectrometry showed the differences in bioactive compounds between unfermented and fermented samples. Trigonelline, determined for the first time in rooibos, ferulic acid and sinapic acid were mainly found in rooibos infusions in comparison to Camellia sinensis teas where these compounds were in lower amounts. Rooibos infusions and Camellia sinensis teas possessed a similar level of 5-, 4-, 3- and 4,5-caffeoylquinic acids. The level of catechins and epicatechin derivatives was in lower amounts in rooibos infusions compared to green tea infusions. In addition, Principal Component Analysis was done to show the significant difference between these two plants.
... Polyphenols are increasingly understood to be important modulators of metabolic, cognitive and musculoskeletal health (Inchingolo et al., 2022;Kujawska & Jodynis-Liebert, 2018;Sasaki, Nishida, & Shimada, 2018). With respect to bone health, polyphenols may support bone health through antioxidant or anti-inflammatory mechanisms (Ramesh, Jagadeesan, Sekaran, Dhanasekaran, & Vimalraj, 2021). ...
... Rooibos tea (produced from Aspalathus linearis), is free of caffeine and low in tannins (4), and has attracted a lot of research interest. It contains numerous minerals, especially flavonoids such as dihydrochalcones (aspalathin and nothofagin), phenylpropanoids, flavones, and flavonols (4,5), which may have a variety of positive health effects (6). Infusions made from Rooibos tea contain flavonoids and phenolic acids which have anti-oxidative activity (7) because they play an active role in preventing the formation of Reactive Oxygen Species (ROS) (8). ...
Article
Full-text available
Introduction: Natural remedies in the treatment of health conditions are an appealing option for many individuals. Previous studies reported that fermented and unfermented rooibos tea have considerable anti-inflammatory and antioxidative properties. Most of this knowledge, however, originates from animal and cell culture studies. Objectives: The aims of this review are to evaluate the existing, but limited, body of knowledge regarding rooibos tea interventions in humans and to identify the gaps in the literature. Methods: The PRISMA extension for Scoping Reviews (PRISMA-ScR) guidelines were followed in the collation of this scoping review. Among the databases searched were Google Scholar, PubMed, Cochrane Library, Scopus, and Web of Science. Results: This review comprised 18 publications, with half (50%) of the studies being conducted in South Africa. There were 488 participants in all, ranging in age from six to 83 years, in the investigations. Rooibos tea was either fermented, unfermented, or black in 62% of the studies. Doses ranging from 200 mL to 1200 mL were employed. In both healthy and at-risk individuals, rooibos has been shown to enhance lipid profiles, boost antioxidant status, and lower blood glucose levels. The existing findings suggests that rooibos consumption demonstrated to improve lipid profiles, boost antioxidant status, and lower blood glucose levels in both apparently healthy, and individual at-risk individuals or diagnosed of chronic conditions. Conclusion: Thus, it can be presumed that rooibos tea provides some health benefits, yet these findings are based on a limited number of human intervention studies and a small total sample size. Additionally, a variety of rooibos dosages and types of tea in the experiments had inconsistent results that were probably impacted by the amount consumed. Future studies should include a dose-response study in humans, as well as large scaled clinical trials to evaluate the health effects of Rooibos.
... Traditional medicinal uses of Rooibos in South Africa include alleviating infantile colic, allergies, asthma, and dermatological problems [31]. It is asserted that Rooibos has a low toxicity profile with several health benefits [28,32] [36], antimutagenic [37] and antidiabetic [38] properties. ...
Preprint
Full-text available
Rooibos ( Aspalathus linearis ) and Honeybush ( Cyclopia intermedia ) are popular tisanes in South Africa and are of growing interest due to the wide variety of flavonoids and other phytochemicals they contain. Despite their history as herbal teas and traditional medicines, the chemical constituents of these tisanes have yet to be studied for their effects on adenosine receptors. Flavonoids have previously shown promising affinity toward the adenosine receptors. A series of 30 commercially available constituents of Rooibos and Honeybush were investigated via radioligand binding studies to determine their adenosine A 1 and A 2A receptor affinity at both rat and human subtypes in order to establish structure-activity relationships and identify novel adenosine receptor ligands. In addition, in silico evaluations of the 30 test compounds were also performed to investigate their physiochemical and pharmacokinetic properties. The most promising constituent was kaempferol ( 28 ) which showed sub-micromolar affinity towards the rat A 1 subtype (rA 1 K i = 0.7287 μM; hA 1 K i = 9.88 µM) and acted as an antagonist toward adenosine rA 1 receptors. Additionally, quercetin ( 2 ), chrysoeriol ( 8 ), luteolin ( 9 ), eriodyctiol ( 12 ), and naringenin ( 27 ) also showed adenosine A 1 and/or A 2A receptor affinity. It was observed that a flavonol scaffold is preferred to flavone and flavanone scaffolds, and within the flavonols, C4’-OH substitution on ring B is preferred to C3’,4’-diOH substitution. These phytochemicals, specifically kaempferol ( 28 ), may be considered lead-like and valuable in designing novel ligands, based on in vitro and in silico evaluation.
... Aspalathin has shown to demonstrate its beneficial effects in model systems of metabolic disease, characterized by the impairment of the cells ROS handling capacity (Sasaki et al. 2018). In neurodegeneration, specifically in AD, similar metabolic perturbation and dysregulation has been described, hence its referral to 'type III diabetes' (Jash et al. 2020). ...
Article
Full-text available
Impaired mitochondrial function and loss of cellular proteostasis control are key hallmarks of aging and are implicated in the development of neurodegenerative diseases. A common denominator is the cell’s inability to handle reactive oxygen species (ROS), leading to major downstream oxidative damage that exacerbates neuronal dysfunction. Although we have progressed in understanding the molecular defects associated with neuronal aging, many unanswered questions remain. How much ROS is required to serve cellular function before it becomes detrimental and how does the cell’s oxidative status impact mitochondrial function and protein degradation through autophagy? How does ROS regulate autophagy? Aspalathus linearis, also commonly known as rooibos, is an endemic South African plant that is gaining globally acclaim for its antioxidant properties and its role as functional medicinal beverage. In this article we dissect the role of rooibos in the context of the cell’s ROS handling capacity, mitochondrial function and autophagy activity. By addressing the dynamic relationship between these critical interconnected systems, and by evaluating the functional properties of rooibos, we unravel its position for preserving cell viability and promoting healthy aging.
... Others focused on cardiovascular disease (CVD) (Smith and Swart, 2018;Windvogel, 2019;Maarman, 2019), cardioprotective effects relating to hyperglycaemia-induced injury (Dludla et al., 2017), metabolic syndrome Johnson et al., 2018) and ovarian health (Sirotkin, 2021). Sasaki et al. (2018) made a systematic review and meta-analysis of the beneficial role of rooibos in diabetes mellitus. Bond and Derbyshire (2020) wrote a systematic review of rooibos tea and health, encompassing evidence from the last two decades. ...
Chapter
Aspalathus linearis (Burm.f) R.Dahlgren, commonly referred to as ‘rooibos tea’, is the best-known indigenous South African herbal tea. It is considered the success story of indigenous product development and marketing, and it is a prime export product, marketed globally. Rooibos is endemic to the Fynbos Biome and is found in the far southwestern part (Nieuwoudtville) of the Northern Cape Province, but chiefly in the Citrusdal and Clanwilliam regions (Cederberg area) of the Western Cape Province. Rooibos tea is anecdotally consumed to relieve colic, indigestion, heartburn and nausea. It also reduces nervous tension, promotes sound sleep and improves appetite. Rooibos extracts are included as anti-oxidant in a wide range of nutraceutical products. The use of rooibos extract in products for topical application for a range of dermatological issues and in a collection of skin-care products is well-established in South Africa. The ‘fermentation’ process is important for the development of the characteristic aroma, flavour and colour of the ‘traditional’ tea product, notable for its red–brown colour. The phytochemistry of rooibos tea has been extensively investigated, especially with regard to the aspalathin (dihydrochalcone) content and that of other major flavonoids, and the quantitative differences between unfermented (green) and fermented rooibos. Much has been documented concerning the anti-oxidant activity of rooibos tea and its role in alleviating oxidative stress. The potential of rooibos, in particular green rooibos extract and aspalathin, in the prevention of metabolic syndrome has been the focus of many studies. Other investigations include antispasmodic, anticancer, bone health and antistress activities. High-performance liquid chromatography (HPLC) with diode array detection (DAD) has been used extensively for the quantification of aspalathin, other major flavonoids and Z-2-(β-d-glucopyranosyloxy)-3-phenylpropenoic acid in rooibos. Other techniques, such as semi-automated high-performance thin-layer chromatography (HPTLC), ultra-performance liquid chromatography coupled to mass spectrometry (UPLC–MS), and mid-infrared (MIR) spectroscopy, were used to determine the chemical profiles of rooibos tea.
Article
Full-text available
Oxidative stress due to obesity plays a detrimental role in the testicular microenvironment and sperm parameters. We explored the impact of a hypercaloric diet in male BALB/c mice as a condition to trigger damage to the spermatogenic process and the antioxidant effect of Aspalathus linearis as well. We used a hypercaloric diet in animals divided into 3 groups: Control, Hypercaloric diet control (HC) and Hypercaloric diet and Rooibos infusion (HCR). Morphometric parameters, enzyme dosages, cell viability, and tubular histopathology were evaluated. Body weight increased in HCR animals at weeks 3, 4, and 8. We found a reduction in seminiferous epithelium height, with an increase in the tubular diameter of the HCR group. Catalase levels were lower in HC and HCR, while carbonyl protein was decreased in HC. We estimate that it induces oxidative stress (OS) capable of affecting the seminiferous epithelium and that the infusion of A. linearis does not demonstrate a potential benefit in cell preservation.
Article
Introduction Rooibos (Aspalathus linearis) is a South African herbal tisane that is enjoyed throughout the world for its taste and emerging health benefits. Rooibos possesses a unique composite of phytochemicals known to encompass antioxidant and bioactive properties and has been suggested as an intervention for several disease conditions. The current study aims to provide a comprehensive bibliometric overview of the literature on Rooibos and its proposed health benefits to complement previous review articles. Methods: A bibliometric mapping analysis of the research on Rooibos was carried out, using data from the titles, abstracts, and keywords of articles published in leading journals and other peer-reviewed documents available in the Scopus database from 1962 to 2021 (21 September), and subsequently analyzed with the VOSviewer software. Results The search yielded 635 documents. The numbers of original articles (n = 525) and reviews (n = 51) were in the ratio of 10:1. More than half of the papers have been published since 2015. These publications were mainly published in journals representing the emerging ethnopharmacological potential of this tisane. Discussion/Conclusion The literature mainly focused on Rooibos bioactive effects against cancer, inflammation, and oxidative stress. Purified Rooibos phytocompounds that were frequently mentioned in the keywords of evaluated publications included aspalathin, quercetin, rutin and the umbrella term “polyphenols”. The accumulating research clearly underlines the benefits of Rooibos as both a preventative and complementary therapeutic functional food. This first attempt to visualize the bibliometrics and altmetrics of Rooibos and its health applications is a good starting point for further scientific work.
Article
Full-text available
Objective Previous studies demonstrated that circulating microRNA-375 (miR-375) is a suitable plasma biomarker for real-time detection of beta cell death. The present study evaluated the use of this biomarker to assess the beta cytoprotective effect of phenylpropenoic acid glucoside (PPAG), which was previously demonstrated to protect beta cells against various types of injury, and of exendin-4, which is an established antidiabetic drug. Methods PPAG or exendin-4 were administered in mice treated with streptozotocin (STZ) to acutely induce beta cell death. Beta cell mass and apoptotic death were measured in pancreatic tissue sections. Circulating miR-375 was measured in blood plasma by RT-qPCR. The release of miR-375 was also measured in vitro by MIN-6 beta cells. Results Administration of STZ resulted in measurable circulating levels of miR-375, a decrease in beta cell mass and increase in frequency of apoptotic beta cells. In vitro, there was a good correlation between miR-375 release and the extent of beta cell death. Treatment of mice with PPAG or exendin-4 significantly attenuated STZ-induced loss of beta cell mass and beta cell apoptosis, and normalized the blood level of miR-375. Conclusions These findings show the potential use of serological miR-375 measurements to evaluate the beta cytoprotective effect of (potential) antidiabetic drugs in vivo.
Article
Full-text available
Diabetic patients are at an increased risk of developing heart failure when compared to their non-diabetic counter parts. Accumulative evidence suggests chronic hyperglycemia to be central in the development of myocardial infarction in these patients. At present, there are limited therapies aimed at specifically protecting the diabetic heart at risk from hyperglycemia-induced injury. Oxidative stress, through over production of free radical species, has been hypothesized to alter mitochondrial function and abnormally augment the activity of the NADPH oxidase enzyme system resulting in accelerated myocardial injury within a diabetic state. This has led to a dramatic increase in the exploration of plant-derived materials known to possess antioxidative properties. Several edible plants contain various natural constituents, including polyphenols that may counteract oxidative-induced tissue damage through their modulatory effects of intracellular signaling pathways. Rooibos, an indigenous South African plant, well-known for its use as herbal tea, is increasingly studied for its metabolic benefits. Prospective studies linking diet rich in polyphenols from rooibos to reduced diabetes associated cardiovascular complications have not been extensively assessed. Aspalathin, a flavonoid, and phenylpyruvic acid-2-O-β-D-glucoside, a phenolic precursor, are some of the major compounds found in rooibos that can ameliorate hyperglycemia-induced cardiomyocyte damage in vitro. While the latter has demonstrated potential to protect against cell apoptosis, the proposed mechanism of action of aspalathin is linked to its capacity to enhance the expression of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) expression, an intracellular antioxidant response element. Thus, here we review literature on the potential cardioprotective properties of flavonoids and a phenylpropenoic acid found in rooibos against diabetes-induced oxidative injury.
Article
Full-text available
Background The potential application of Ficus deltoidea and vitexin for the management of symptomatologies associated with diabetes mellitus (DM) has gained much attention. However, less firm evidence comes from data to augment our understanding of the role of F. deltoidea and vitexin in protecting pancreatic β-cells. The aim of this study was to assess histological and oxidative stress changes in the pancreas of streptozotocin (STZ)-induced diabetic rats following F. deltoidea extract and vitexin treatment. Methods F. deltoidea and vitexin was administrated orally to six-weeks STZ-induced diabetic rats over 8 weeks period. The glucose and insulin tolerances were assessed by intraperitoneal glucose (2 g/kg) tolerance test (IPGTT) and intraperitoneal insulin (0.65 U/kg) tolerance test (IPITT), respectively. Subsequently, insulin resistance was assessed by homeostasis assessment model of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI) and the insulin/triglyceride-derived McAuley index. The histological changes in the pancreas were then observed by hematoxylin-eosin (H&E) staining. Further, the pattern of fatty acid composition and infrared (IR) spectra of the serum and pancreas were monitored by gas chromatography (GC) method and Fourier Transform Infrared (FT-IR) spectroscopy. Results F. deltoidea and vitexin increased pancreatic antioxidant enzymes and promoted islet regeneration. However, a significant increase in insulin secretion was observed only in rats treated with F. deltoidea. More importantly, reduction of fasting blood glucose is consistent with reduced FT-IR peaks at 1200-1000 cm⁻¹. Conclusions These results accentuate that F. deltoidea and vitexin could be a potential agent to attenuate pancreatic oxidative damage and advocate their therapeutic potential for treating DM.
Article
Full-text available
Aspalathin, a C-glucosyl dihydrochalcone, has previously been shown to protect cardiomyocytes against hyperglycemia-induced shifts in substrate preference and subsequent apoptosis. However, the precise gene regulatory network remains to be elucidated. To unravel the mechanism and provide insight into this supposition, the direct effect of aspalathin in an isolated cell-based system, without the influence of any variables, was tested using an H9c2 cardiomyocyte model. Cardiomyocytes were exposed to high glucose (33 mM) for 48 h before post-treatment with or without aspalathin. Thereafter, RNA was extracted and RT² PCR Profiler Arrays were used to profile the expression of 336 genes. Results showed that, 57 genes were differentially regulated in the high glucose or high glucose and aspalathin treated groups. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analysis revealed lipid metabolism and molecular transport as the biological processes altered after high glucose treatment, followed by inflammation and apoptosis. Aspalathin was able to modulate key regulators associated with lipid metabolism (Adipoq, Apob, CD36, Cpt1, Pparγ, Srebf1/2, Scd1 and Vldlr), insulin resistance (Igf1, Akt1, Pde3 and Map2k1), inflammation (Il3, Il6, Jak2, Lepr, Socs3, and Tnf13) and apoptosis (Bcl2 and Chuk). Collectively, our results suggest that aspalathin could reverse metabolic abnormalities by activating Adipoq while modulating the expression of Pparγ and Srebf1/2, decreasing inflammation via Il6/Jak2 pathway, which together with an observed increased expression of Bcl2 prevents myocardium apoptosis.
Article
Full-text available
Aspalathin (ASP) can protect H9c2 cardiomyocytes against high glucose (HG)-induced shifts in myocardial substrate preference, oxidative stress, and apoptosis. The protective mechanism of ASP remains unknown. However, as one of possible, it is well known that phytochemical flavonoids reduce oxidative stress via nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activation resulting in up-regulation of antioxidant genes and enzymes. Therefore, we hypothesized that ASP protects the myocardium against HG- and hyperglycemia-induced oxidative damage by up-regulating Nrf2 expression in H9c2 cardiomyocytes and diabetic (db/db) mice, respectively. Using an oxidative stress RT² Profiler PCR array, ASP at a dose of 1 µM was demonstrated to protect H9c2 cardiomyocytes against HG-induced oxidative stress, but silencing of Nrf2 abolished this protective response of ASP and exacerbated cardiomyocyte apoptosis. Db/db mice and their non-diabetic (db/+) littermate controls were subsequently treated daily for six weeks with either a low (13 mg/kg) or high (130 mg/kg) ASP dose. Compared to nondiabetic mice the db/db mice presented increased cardiac remodeling and enlarged left ventricular wall that occurred concomitant to enhanced oxidative stress. Daily treatment of mice with ASP at a dose of 130 mg/kg for six weeks was more effective at reversing complications than both a low dose ASP or metformin, eliciting enhanced expression of Nrf2 and its downstream antioxidant genes. These results indicate that ASP maintains cellular homeostasis and protects the myocardium against hyperglycemia-induced oxidative stress through activation of Nrf2 and its downstream target genes.
Article
Full-text available
Healthy kidneys filter ∼160 g/day of glucose (∼30% of daily energy intake) under euglycaemic conditions. To prevent valuable energy from being lost in the urine, the proximal tubule avidly reabsorbs filtered glucose up to a limit of ∼450 g/day. When blood glucose levels increase to the point that the filtered load exceeds this limit, the surplus is excreted in the urine. Thus, the kidney provides a safety valve that can prevent extreme hyperglycaemia as long as glomerular filtration is maintained. Most of the capacity for renal glucose reabsorption is provided by sodium glucose cotransporter (SGLT) 2 in the early proximal tubule. In the absence or with inhibition of SGLT2, the renal reabsorptive capacity for glucose declines to ∼80 g/day (the residual capacity of SGLT1), i.e. the safety valve opens at a lower threshold, which makes it relevant to glucose homeostasis from day-to-day. Several SGLT2 inhibitors are now approved glucose lowering agents for individuals with type 2 diabetes and preserved kidney function. By inducing glucosuria, these drugs improve glycaemic control in all stages of type 2 diabetes, while their risk of causing hypoglycaemia is low because they naturally stop working when the filtered glucose load falls below ∼80 g/day and they do not otherwise interfere with metabolic counterregulation. Through glucosuria, SGLT2 inhibitors reduce body weight and body fat, and shift substrate utilisation from carbohydrates to lipids and, possibly, ketone bodies. Because SGLT2 reabsorbs sodium along with glucose, SGLT2 blockers are natriuretic and antihypertensive. Also, because they work in the proximal tubule, SGLT2 inhibitors increase delivery of fluid and electrolytes to the macula densa, thereby activating tubuloglomerular feedback and increasing tubular back pressure. This mitigates glomerular hyperfiltration, reduces the kidney's demand for oxygen and lessens albuminuria. For reasons that are less well understood, SGLT2 inhibitors are also uricosuric. These pleiotropic effects of SGLT2 inhibitors are likely to have contributed to the results of the EMPA-REG OUTCOME trial in which the SGLT2 inhibitor, empagliflozin, slowed the progression of chronic kidney disease and reduced major adverse cardiovascular events in high-risk individuals with type 2 diabetes. This review discusses the role of SGLT2 in the physiology and pathophysiology of renal glucose reabsorption and outlines the unexpected logic of inhibiting SGLT2 in the diabetic kidney.
Article
Full-text available
Increasing energy expenditure through activation of brown adipose tissue (BAT) is a critical approach to treating obesity and diabetes. In this study, rutin, a natural compound extracted frommulberry and a drug used as a capillary stabilizer clinically formany yearswithout any side effects, regulated whole-body energymetabolism by enhancing BAT activity. Rutin treatment significantly reduced adiposity, increased energy expenditure, and improved glucose homeostasis in both genetically obese (Db/Db) and diet-induced obesity (DIO) mice. Rutin also induced brown-like adipocyte (beige) formation in subcutaneous adipose tissue in both obesity mouse models. Mechanistically, we found that rutin directly bound to and stabilized SIRT1, leading to hypoacetylation of peroxisome proliferator-activated receptor g coactivator-1a protein, which stimulated Tfam transactivation and eventually augmented the number of mitochondria and UCP1 activity in BAT. These findings reveal that rutin is a novel small molecule that activates BAT and may provide a novel therapeutic approach to the treatment of metabolic disorders.-Yuan, X.,Wei, G., You, Y.,Huang, Y., Lee,H. J.,Dong,M., Lin, J.,Hu, T., Zhang,H.,Zhang,C.,Zhou,H., Ye, R., Qi, X., Zhai, B., Huang, W., Liu, S., Xie, W., Liu, Q., Liu, X., Cui, C., Li, D., Zhan, J., Cheng, J., Yuan, Z., Jin, W. Rutin ameliorates obesity through brown fat activation. FASEB J. 31, 333-345 (2017). www.fasebj.org.
Article
We review here the case histories and results of in vivo and in vitro tests for eight children with congenital selective glucose and galactose malabsorption (GGM) whom our laboratory has followed up since 1971. Clinically, GGM was manifested by intractable, acidic, sugar‐containing diarrhea that started during the neonatal period. Diarrhea only abated when glucose and galactose were removed from the diet. The disease was notable for the absence of other symptoms, although mellituria was a common finding. Defective sugar transport was permanent, but sugar tolerance appeared to increase with age. In vitro, intracellular mucosal glucose concentration ( C ) was significantly below control level in GGM intestinal tissue for concentrations ( M ) of 10 and 0.1 m M glucose in the medium. C/M for galactose also decreased, while the C/M ratios for alanine and xylose were within the control range. Glucose influxes across the luminal membrane, net glucose transepithelial fluxes, and electrical parameters were all consistent with defective sodium and glucose cotransport at the brush border membrane of jejunal epithelial cells. However, the present results are also consistent with a small residual active transport system observed only at low glucose concentration in the medium. Further observations are needed to establish the role of glucose transport systems in absorption of other monosaccharides, the relationship between kidney and intestinal sodium‐glucose cotransport systems, and their genetic control.
Article
Inhibiting glucose reabsorption by sodium glucose co-transporter proteins (SGLTs) in the kidneys is a relatively new strategy for treating type 2 diabetes. Selective inhibition of SGLT2 over SGLT1 is critical for minimizing adverse side effects associated with SGLT1 inhibition. A library of C-glucosyl dihydrochalcones and their dihydrochalcone and chalcone precursors was synthesized and tested as SGLT1/SGLT2 inhibitors using a cell-based fluorescence assay of glucose uptake. The most potent inhibitors of SGLT2 (IC50 = 9-23 nM) were considerably weaker inhibitors of SGLT1 (IC50 = 10-19 μM). They showed no effect on the sodium independent GLUT family of glucose transporters, and the most potent ones were not acutely toxic to cultured cells. The interaction of a C-glucosyl dihydrochalcone with a POPC membrane was modelled computationally, providing evidence that it is not pan-assay interference compound (PAINS). These results point toward the discovery of structures that are potent and highly selective inhibitors of SGLT2.